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Abstract: The serine protease thrombin plays a role in signalling ischemic neuronal death 
in the brain. Paradoxically, endogenous neuroprotective mechanisms can be triggered by 
preconditioning with thrombin (thrombin preconditioning, TPC), leading to tolerance to 
cerebral ischemia. Here we studied the role of thrombin’s endogenous potent inhibitor, 
protease nexin-1 (PN-1), in ischemia and in tolerance to cerebral ischemia induced by 
TPC. Cerebral ischemia was modelled in vitro in organotypic hippocampal slice cultures 
from rats or genetically engineered mice lacking PN-1 or with the reporter gene lacZ 
knocked into the PN-1 locus PN-1HAPN-1-lacZ/HAPN-1-lacZ (PN-1 KI) exposed to 
oxygen and glucose deprivation (OGD). We observed increased thrombin enzyme activity 
in culture homogenates 24 h after OGD. Lack of PN-1 increased neuronal death in the 
CA1, suggesting that endogenous PN-1 inhibits thrombin-induced neuronal damage after 
ischemia. OGD enhanced β-galactosidase activity, reflecting PN-1 expression, at one and 
24 h, most strikingly in the stratum radiatum, a glial cell layer adjacent to the CA1 layer of 
ischemia sensitive neurons. TPC, 24 h before OGD, additionally increased PN-1 
expression 1 h after OGD, compared to OGD alone. TPC failed to induce tolerance in 
cultures from PN-1−/− mice confirming PN-1 as an important TPC target. PN-1 
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upregulation after TPC was blocked by the c-Jun N-terminal kinase (JNK) inhibitor,  
L-JNKI1, known to block TPC. This work suggests that PN-1 is an endogenous 
neuroprotectant in cerebral ischemia and a potential target for neuroprotection. 
Keywords: protease nexin-1; thrombin preconditioning; cerebral ischemia; organotypic 
hippocampal slice cultures; glucose and oxygen deprivation; c-Jun N-terminal kinase; 
stroke; neuroprotection 
 
1. Introduction 
Stroke is a leading cause of mortality and disability worldwide and results mostly from an ischemia 
of part of the brain, triggering cell death pathways which lead to both rapid and delayed injury to the 
brain parenchyma. Thrombolysis within 4.5 h from symptom onset, the only currently available 
specific treatment for ischemic stroke, can be administered to only approximately 10% of patients 
hence the need for alternative treatments such as neuroprotective approaches [1]. Tolerance to 
ischemia can be elicited by exposure to a low intensity noxious stimulus (preconditioning) [2]. The 
tolerance to subsequent ischemia induced by the administration of a low dose of the serine protease 
thrombin [3–5] may provide opportunities to identify some of the molecules involved in endogenous 
neuroprotective mechanisms [6]. This phenomenon seems a paradox given that thrombin extravasation 
is considered as an important cause of brain cell damage and high doses of thrombin injected directly 
into the brain elicit oedema and neurotoxicity [7,8]. Recently, an in vivo study using an ACPP 
(activated cell penetrating peptide) imaging probe to detect the proteolytic activity of thrombin, 
showed that early activation of thrombin during acute focal cerebral ischemia strongly correlated with 
neurovascular damage in the ischemic core [9]. Thrombin can be inhibited by serine protease 
inhibitors, such as antithrombin III or protease nexin-1 (PN-1). PN-1 is a glia-derived secreted 43 kD 
protein, member of the serpin family, with neurite outgrowth promoting activity [10]. It is a very 
potent inhibitor of thrombin and also inhibits Factor Xa, Factor XIa, tPA, uPA and plasmins. It is 
expressed in many organs including the brain and vessel walls. PN-1 is currently considered an 
important regulator of thrombin in both the intra- and extravascular space (for review [11]).  
Thrombin induces both tolerance and cell death through proteolytic cleavage of the protease-activated 
receptor-1 (PAR-1), with the GTPase RhoA being involved in both cases [4]. Low concentrations 
(0.01 U/mL) of mouse thrombin added to organotypic hippocampal slices, 24 h before OGD, attenuate 
death of CA1 neurons [5]. It has been shown that these neuroprotective thrombin concentrations 
induce Ca2+ spikes, while higher, toxic concentrations induce sustained Ca2+ entry into CA1 neurons of 
hippocampal slices [12]. In vivo, intracerebroventricular (i.c.v.) injection of 0.01 U of mouse thrombin, 
24 h before 30 min middle cerebral artery occlusion (MCAO) in mice, reduces the infarct volume and 
improves the behavioural outcome [5]. In rat models, TPC requires activation of the extracellular 
signal-regulated kinases 1 and 2 (ERK1/2) pathways [13,14]. The ERK1/2 inhibitor, PD98059, 
prevents the protective effect. TPC also increases hypoxia inducible factor-1α [15] and heat shock 
proteins proposed as putative downstream effectors controlling the extent of damage [3].  
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On the contrary, strong protection is achieved by intra-cerebral injection of hirudin, a potent 
thrombin inhibitor from leech, before rat MCAO [16] or global cerebral ischemia in gerbils [12].  
In blood free organotypic rat hippocampal slice cultures, ischemia which is modelled by OGD, triggers 
the generation of thrombin [17]. Both hirudin and PN-1 lead to neuroprotection when added after OGD 
demonstrating a role of thrombin signalling in ischemic damage in neural tissue. Thrombin thereby 
appears to play a dual paradoxical role in cerebral ischemia. Interestingly, the inhibition of the c-Jun 
N-terminal kinase (JNK) prevents the neuroprotection induced by TPC [5]. As JNK inhibition strongly 
protects in rodent models of cerebral ischemia [18–20], JNK appears to have a similar dual function. 
PN-1 expression is increased after global ischemia [21,22] and after intracerebral haemorrhage [23]. 
This serpin is therefore likely to play a key role as regulator of thrombin activity following brain 
injury. Consequently, we investigated its function in cerebral ischemia using newly available 
genetically modified mice: PN-1 knockout mice and knock-in animals expressing a reporter gene in 
the PN-1 locus [24,25]. Our results indicate that PN-1 may be involved in the endogenous defence 
mechanisms triggered by TPC.  
2. Results and Discussion 
2.1. Thrombin Activity Is Increased in Brain Tissue after Ischemia in Vitro 
Thrombin appears to play a role as a mediator of ischemic neuronal death in the cerebral 
parenchyma. Prothrombin was detected in organotypic hippocampal slice cultures by Western blotting 
and was shown to be converted to thrombin in response to OGD [17]. We tested whether this increased 
thrombin immunoreactivity, after a 30 min OGD followed by 24 h reoxygenation, corresponds to 
increased thrombin protease activity in the hippocampal slices. Using a chromogenic substrate for 
thrombin, we evaluated thrombin protease activity in hippocampal slice culture homogenates and 
compared it to the activity of purified mouse thrombin. 24 h after OGD, there was a significant 
increase in thrombin activity, demonstrating activation of thrombin in response to ischemia (Figure 1). 
This thrombin protease activity, produced in an in vitro “blood-free” system correlates with neuronal 
cell death observed in the slices 24 h after OGD.  
Figure 1. Thrombin activity is increased after OGD. Thrombin enzyme activity in 
hippocampal slice culture homogenates was assayed using a chromogenic substrate with 
purified recombinant mouse thrombin as a standard. The results were expressed as units of 
thrombin/mg of protein. Thrombin enzyme activity is significantly (Kruskall Wallis test  
p = 0.0006, followed by Mann-Whitney test p < 0.05) increased in hippocampal slice 
cultures 24 h after oxygen and glucose deprivation (OGD). (* p < 0.05). 
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2.2. Endogenous PN-1 Protects against Ischemic Neuronal Death in Hippocampal Slices after OGD 
As the addition of recombinant PN-1 after OGD attenuates ischemic neuronal death [17], we 
investigated the role of endogenous PN-1 in cerebral ischemia by subjecting hippocampal slices from 
mice lacking PN-1 [24] to OGD. Neuronal death 48 h after OGD was significantly higher in slices 
from mice lacking PN-1 than from control mice, with intermediate results in heterozygotes, 
demonstrating that endogenous PN-1 has a protective role, most likely by attenuating the detrimental 
action of thrombin (Figure 2). 
Figure 2. Enhanced sensitivity to OGD in the absence of PN-1. The role of PN-1 in 
cerebral ischemia was evaluated by subjecting mouse hippocampal slice cultures to OGD 
and measuring neuronal cell death in the CA1 by propidium iodide uptake. Mutant mice 
lacking one allele of PN-1 (heterozygotes, HET) were not significantly different from wild 
type mice (WT). In PN-1 knockout mice (KO) however, the amount of cell death was 
significantly higher than in wild types or heterozygotes (one-way ANOVA followed by 
Tukey-Kramer, p < 0.01). N represents the number of wells containing 3 to 5 slices each. 
(** p < 0.01). 
 
2.3. PN-1 Is Upregulated after OGD and Thrombin Preconditioning 
As thrombin can induce tolerance to ischemia [6], PN-1 may be a potential key player in thrombin 
preconditioning, which could result in an enhanced PN-1 expression. To test this possibility, we used 
knock-in mice (PN-1 KI) expressing the β-galactosidase reporter gene under the control of the PN-1 
promoter [25]. The presence of β-galactosidase, reflecting PN-1 transcription, was revealed in 
hippocampal slices by X-gal staining (Figure 3, panels A to D). The staining was most prominent in 
the stratum radiatum, a glial cell region in the vicinity of the ischemia sensitive CA1 neurons. The 
expression of β-galactosidase was significantly enhanced both 1 h (control vs. OGD, Figure 3) and  
24 h after OGD onset (not shown). Having shown previously that thrombin signalling after OGD 
occurs rapidly, as hirudin administered immediately after OGD for 1 h conferred the same protection 
as hirudin applied for 24 h after OGD [17], we focused on the 1 h time-point. TPC alone further 
significantly enhanced the expression of PN-1 in the stratum radiatum compared to OGD alone (TPC 
vs. OGD, Figure 3), as did TPC 24 h before OGD (TPC+OGD vs. OGD, Figure 3). Similar results 
were obtained by performing β-galactosidase assays on slice culture homogenates (data not shown). 
Increased PN-1 protein is observed on Western blots 1 h and 24 h after OGD and after TPC in a model 
system using rat hippocampal slices subjected to OGD. Comparable results were observed for TPC 
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when using thrombin receptor agonist or thrombin, indicating that upregulation of PN-1 is via the 
PAR-1 receptor (data not shown and [6]). Also, we observed qualitative increases in PN-1 
transcription in vivo in KI mice after injecting preconditioning doses of thrombin into the lateral 
ventricles and after MCAO modeled ischemia (data not shown). 
Figure 3. TPC enhances PN-1 transcription in vitro. Organotypic hippocampal slice 
cultures from PN-1 KI mice expressing the β-galactosidase protein under the control of the 
PN-1 promoter were used. X-gal staining reflecting β-galactosidase activity was detected 
and quantitated in the stratum radiatum. The stratum radiatum was identified by double 
labellling with X-gal and the neuronal marker Neu N, which labels the neuronal layers. The 
major site of X-Gal labelling did not coincide with Neu N labelling suggesting glial cell 
labelling. Compared to controls (A), OGD (B) significantly enhanced PN-1 expression. 
TPC alone (C) further enhanced the expression of PN-1 (ANOVA followed by  
Tukey-Cramer, p < 0.001, compared to OGD alone). If OGD was preceded by TPC,  
(D), the expression was significantly higher than with OGD alone (ANOVA followed by 
Tukey-Cramer, p < 0.001). N represents the total number of slices. A high magnification 
image of X-gal stained cells is inserted into the right-hand corner of image B. (** p < 0.01; 
*** p < 0.001). 
 
The upregulation of endogenous PN-1 in response to ischemia and to thrombin preconditioning 
confirms a role for the serpin as a regulator of thrombin activity after ischemia and in TPC and 
suggests that PN-1 has a neuroprotective role in OGD.  
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2.4. Endogenous PN-1 Is Necessary for Thrombin Induced Ischemic Tolerance in  
Hippocampal Slice Cultures 
To further evaluate the importance of the observed changes, we tested whether cultures from PN-1 
knock-out mice could be preconditioned by thrombin in vitro (Figure 4A). While tissue cultures from 
wild type mice were protected by exposure to 0.01 U/mL of mouse thrombin 24 h before OGD (very 
significant 67% reduction in neuronal death), we did not observe a protection in heterozygotes  
(non-significant 26% reduction in neuronal death) or in knock-outs (non-significant 16% reduction in 
neuronal death). This suggests that endogenous PN-1 is necessary for the induction of tolerance  
by thrombin. 
Figure 4. TPC requires the presence of PN-1. (A) TPC was performed in slices from mice 
lacking PN-1. TPC before OGD significantly (p < 0.001, Kruskall Wallis followed by 
Dunn’s multiple comparisons) attenuated neuronal death in cultures from wild-type mice. 
TPC did not induce a significant protection (ns) in heterozygotes or knock-out mice, 
demonstrating that endogenous PN-1 is required for TPC. N represents the number of 
slices. (*** p < 0.001); (B) Given the identification of PN-1 as a target for TPC, slices 
from PN-1 KI mice were used to test whether the TPC-induced upregulation of PN-1 was 
influenced by the JNK inhibitor L-JNKI1, known to block the protective effect of TPC.  
β-galactosidase positive cells in the stratum radiatum were counted. TPC enhanced the 
expression of PN-1 (ANOVA p < 0.0001, Tukey-Cramer p < 0.001) while L-JNKI1 alone 
did not. The addition of L-JNKI1 after TPC significantly reduced the PN-1 upregulation 
(ANOVA p < 0.0001, Tukey-Cramer p < 0.001 compared to TPC alone). (*** p < 0.001). 
  
2.5. PN-1 Upregulation in Hippocampal Slices Is Prevented by Inhibiting the  
c-Jun-N-Terminal Kinase (JNK) 
In vivo L-JNKI1, a cell permeable peptide inhibitor of JNK, prevents TPC [5]. In vitro, both  
L-JNKI1 and the small molecule JNK inhibitor SP600125 prevented thrombin-induced tolerance [5,6]. 
Having identified PN-1 as a target for TPC we tested the effect of L-JNKI1 on the upregulation of  
PN-1 in PN-1 KI mice. While L-JNKI1 alone had no effect on the baseline expression of PN-1, it 
blocked the very significant 2.6 fold PN-1 upregulation after thrombin preconditioning (Figure 4B), 
further supporting a role for PN-1 in thrombin-induced tolerance to ischemia. 
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2.6. Discussion 
The protease-activated receptors, the serpin PN-1 and Factor X, main players involved in thrombin 
signalling and regulation are detected in the brain [10,26–29] and increasing evidence indicates that the 
clotting factor thrombin plays a role in the cerebral parenchyma (for review [30]). Using a blood free 
in vitro approach, we previously showed that thrombin protein is detected on Western blots after 
ischemia modelled in vitro by OGD and that specific thrombin and Factor Xa inhibitors confer 
neuroprotection [17,31]. The results presented here make two further points:  
Firstly, we demonstrate an increase in thrombin protease enzyme activity in brain tissue after 
ischemia (Figure 1). This suggests that thrombin may be activated in an in vitro system, free of 
circulating blood. 
Secondly, our observation that CA1 hippocampal neurons from PN-1 knockout mice are 
significantly more susceptible to ischemia (Figure 2) provides strong support for an important function 
of PN-1. It certainly implies that PN-1 can to some extent moderate the deleterious effect of the 
ischemia-induced thrombin activity on neuronal death in wild type mice.  
To further investigate this role of PN-1 in the CNS, we tested cultures from PN-1 knock-in mice in 
which the expression of bacterial β-galactosidase is driven by the PN-1 promoter [25]. While PN-1 is 
secreted, the reporter protein β-galactosidase bears a nuclear localisation signal that remains in the 
nucleus of the cell, thus identifying the site of PN-1 transcription. Detection of the activity of the 
reporter enzyme in homogenates also provides information on the level of expression. We observed 
that β-galactosidase was strongly expressed in hippocampal cultures and the site of highest 
transcription is a glial cell layer, the stratum radiatum, in close vicinity to the pyramidal cell layer of 
the CA1, where most ischemia sensitive neurons reside. A significant increase in β-galactosidase 
activity in the stratum radiatum was detected both after ischemia and TPC (Figure 3). Furthermore, 
TPC, followed 24 h later by OGD, induced a significantly higher β-galactosidase activity than OGD 
alone (Figure 3) This suggests that OGD triggers the expression of PN-1 in an attempt to counteract 
the detrimental increase of thrombin activity and that TPC further enhances this protective mechanism. 
β-galactosidase expression is upregulated in vivo after i.c.v. injection of preconditioning doses of 
thrombin and after MCAO (data not shown). Interestingly, the highest PN-1 expression is in cells 
lining the ventricles which coincides with thrombin receptor PAR-1 expression [32] and therefore 
thrombin, in the ventricles, could trigger the expression of its inhibitor via its receptor in these cells, 
thereby modulating its own activity.  
We performed MCAO experiments on PN-1−/− mice and observed a tendency to slightly larger 
lesions in PN-1−/− mice compared to WT although results were not significant and highly variable 
between experimenters (data not shown). Similarly, there was a trend for a worse behavioural outcome 
in the PN-1−/− mice but again this did not reach significance (data not shown). This may be due to 
compensatory mechanisms in PN-1 knock-out mice and indeed, Hengst et al. [33] commented that 
mice lacking PN-1 show only very subtle phenotypes in the CNS and went on to purify and 
characterize a novel serine protease inhibitor, phosphatidylethanolamine-binding protein from the 
brains of PN-1−/− mice which specifically interferes with thrombin activity. In this respect it will be 
useful to knock-down the activity of PN-1 at selected time points in the mouse brain to investigate the 
role of PN-1 in the absence of possible compensatory mechanisms. As thrombin proteolytic activity is 
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also associated with long-term cognitive deficit [9] it will be interesting to study PN-1 knock-down 
and possible behavioural differences at late time points. Cultures from PN-1 deficient mice and 
heterozygotes with a single PN-1 allele failed to develop significant protection after TPC while TPC 
induced significant protection in slices from wild type littermates (Figure 4A). Endogenous PN-1 is 
required for tolerance induced by TPC, and may therefore be an important target for TPC. Indeed, 
administration of L-JNKI1 [5,6,34] after TPC prevented the enhanced PN-1 expression (Figure 4B), 
providing an additional argument for an important role of PN-1 in TPC.  
High doses of thrombin injected into the brain trigger cerebral oedema and it is also known that the 
oedema occurring after intracerebral haemorrhage (ICH) is partly due to thrombin (for review [35]). 
Oedema is also an aggravating factor in cerebral ischemia. Taking into account these deleterious 
effects, it is important to better understand the protective impact of TPC, both upstream and 
downstream of thrombin, to characterise the molecules involved. We have identified a downstream 
target of TPC, the water channel aquaporin 4 (AQP4), which is upregulated on astrocytic endfeet 1 h 
after ischemia onset and which prevents the occurrence of early cerebral oedema [36,37]. This 
supports interplay between thrombin and AQP4. Others have shown that thrombin induces either cell 
death or protection in primary astrocytic cultures via PAR-1 activation of the small GTPase  
RhoA [4,38–40]. Thrombin triggers a protective mechanism via PAR-dependent astrocytic  
release of chemokine growth-regulated oncogene/cytokine-induced neutrophil chemoattractant-1 
(GRO/CINC-1) [41–43]. Given our present demonstration that PN-1 is a necessary target in TPC, it 
will be interesting to study to what extent this serpin affects AQP4, PAR activation, small GTPase 
RhoA and GRO/CINC-1. A further exciting approach will be to use the presence or absence of PN-1 
and other TPC targets to investigate at which point the thrombin pathway diverges to signal cell death 
or survival. 
3. Experimental Section  
3.1. Animals  
All animal experiments were conducted in accordance with the European guidelines and were 
approved by the local authority (cantonal veterinary office). Wild type rats (OFA Sprague Dawley, 
Charles River, France) [20,44] and wild type mice (C57Bl6 Charles River, France) were used in our 
experiments. Mutant mice were obtained from the laboratory of Pr. Denis Monard, Friedrich-Miescher 
Institute, Basel: PN-1 knock-in mice with insertion of the β-galactosidase coding sequence behind the 
PN-1 coding sequence: PN-1HAPN-1-lacZ/HAPN-1-lacZ [25]; PN-1 knock-out mice, bred by 
crossing PN-1+/− mice [24]). Heterozygous mating generated PN-1 KO and wild-type littermates. 
These PN-1 deficient mice are phenotypically normal apart from male infertility [45]. Genotyping was 
performed by PCR of DNA from tail biopsies [25]. 
3.2. Organotypic Hippocampal Slice Cultures 
Organotypic hippocampal slice cultures were prepared as previously described from 10 to 12  
day-old rats (OFA Sprague Dawley, Charles River, France) [20,44] or from 12-day old wild type 
(C57Bl6 Charles River, France) or mutant mice (PN-1 knock-in mice; PN-1 knock-out mice). Coronal 
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hippocampal sections (350 µm) were placed onto sterile porous membrane units (Millicell-CM, 
Millipore, Billerica, MA, USA) in wells containing 1 mL of culture medium consisting of 50% MEM 
supplemented with HEPES and sodium bicarbonate, 25% Hank’s salt solution, 25% horse serum,  
2 mM L-glutamine and 35 mM D-glucose. Cultures were kept at 33 °C, 100% humidity, 5% CO2 for  
4 days, and then transferred to culture medium with 15% horse serum and 5 mM D-glucose, which was 
changed every 3 to 4 days. Experiments were started after 7 days of culture. 
3.3. Oxygen and Glucose Deprivation (OGD) in Organotypic Hippocampal Slice Cultures 
OGD experiments were performed as previously described in serum free hypoglycaemic DMEM 
medium (D5030, Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1 mM D-glucose and 2 mM 
L-glutamine [17]. This medium was equilibrated for 1 h at 37 °C, in a humidified chamber (COY, 
Grass Lake, MI, USA) with a hypoxic atmosphere (5% O2, 5% CO2). Slices were transferred into this 
“buffered medium” and into the hypoxic chamber for 30 min. Control cultures were placed in DMEM 
medium supplemented with 5 mM D-glucose and 2 mM L-glutamine for 30 min at 37 °C, in a humid 
normoxic atmosphere. For recovery, cultures were transferred into culture medium at 33 °C for 24 or 
48 h. For thrombin preconditioning, purified mouse thrombin (Sigma, final concentration, 0.01 U/mL) 
was added for 1 h, after which time the medium was changed, 24 h before OGD. Cell death was 
determined in the CA1 after incubating cultures (3–5 slices per culture) for 30 min with the fluorescent 
viability indicator propidium iodide (PI, 5 µg/mL). PI fluorescent emission (excitation wavelength  
568 nm) was measured 24 h or 48 h after ischemia, using an epifluorescence microscope with a  
5× lens coupled to a camera (Leica). PI images were acquired with standardized camera settings and 
optical density was measured with ImageJ software (ImageJ 1.36b, National Institute of Health). After 
subtracting the background fluorescence, results were expressed as a percentage of maximal cell death 
obtained by submerging slices in PBS for 24 h at 4 °C.  
3.4. Chromogenic Thrombin Assay 
Cultured hippocampal slices (5 slices in one microwell) were homogenised in 100 μL of 
homogenizing buffer (20 mM Sodium Phosphate, 0.32 M Sucrose, 1 mM EDTA, 0.2% Tween 20, in 
sterile water). Chromogenic assays were adapted to 96 well microtiter plates. The assay mixture (final 
volume 100 μL/well) included in addition to the samples, or to purified mouse thrombin (from Sigma) 
for standard curves, the following reagents (final concentrations): 67 mM Tris pH 8.0, 0.13% 
polyethylene glycol (PEG) 6000, 133 mM NaCl. The plate was shaken and 125 mg/mL chromogenic 
peptide S-2238 (S-2238TM H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline dihydrochloride, 
stock solution: 1.2 mM in H2O, Chromogenix, Endothell, AG, Allschwil, Switzerland) was added. 
Plates were incubated at 37 °C in a humidified chamber and absorbance was measured at 405 nm in a 
Thermomax microplate reader [46]. To avoid contamination by exogenous thrombin activity from the 
horse serum-containing medium, hippocampal slice cultures were kept in serum free medium for 24 h 
before homogenisation.  
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3.5. β-Galactosidase Enzyme Staining on Hippocampal Slices 
Hippocampal slices or frozen brain cryostat slices were fixed 30 min in 4% PFA/PBS, washed  
3 × 15 min in washing buffer (0.01% NaDOC, 0.02% Nonidet P-40, 5 mM EGTA pH 8.4, 3 mM 
MgCl2, in PBS), and stained with an X-Gal staining solution 10 mM K3Fe(CN)6, 10 mM 
K4(Fe(CN)6)2, 0.25 mg/mL 5-Bromo-4-Chloro-3-Indolyl-b-galactopyranoside (X-Gal, Eppendorf, 
Germany, stock solution 50 mg/mL in Dimethylsulfoxide (DMSO)) during 3–8 h at 37 °C. Slices were 
then washed 5 min in PBS, fixed again in 4% PFA/PBS for 30 min, and finally washed 5 min in PBS. 
The Mercator program (Explora Nova, La Rochelle, France) was used to analyse the β-galactosidase 
staining on hippocampal slice cultures. The blue staining was analysed by computer assisted 
microscopic quantification of the number of positive cells in the stratum radiatum region of 
organotypic hippocampal slices. 
3.6. Statistical Analysis 
Data were expressed as mean ± SD. Statistical evaluation was performed using the Instat software 
(GraphPad, San Diego, CA, USA). In the case of two groups, data were compared with the Mann-Whitney 
test. Comparisons of 3 groups were carried out by ANOVA or by the Kruskall-Wallis test in cases of 
non parametrical data or small sample sizes. Probability values of <0.05 were considered significant. 
4. Conclusions  
Hippocampal slice cultures from Protease nexin-1 deficient mice are more vulnerable to 
experimental ischemia than cultures from wild type animals, indicating that PN-1 is an endogenous 
neuroprotectant. Furthermore, neuroprotection resulting from thrombin preconditioning is associated 
with an upregulation of PN-1 and TPC does not protect PN-1 deficient cultures, highlighting the role 
of PN-1 in tolerance to ischemia triggered by thrombin preconditioning. This work suggests that PN-1 
is an endogenous neuroprotectant in cerebral ischemia and a potential target for neuroprotection. 
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